As far as the vaccines go there is still "promise." Like I previously mentioned I don't believe it will be as a stand alone therapy but in combination with other treatments. It's basically used as a maintenance therapy to help prevent recurrence. From my communication with the company the vaccine trials will continue to progress. They aren't going to scrap them but its obvious the MultiTAA will be the focal point of the company moving forward. As far as how promising the MultiTAA therapy is all we have to go off of are the data that has been presented. From that, it clearly is very compelling and hopefully future data just continues to build onto it. I can say with almost 100% certainty that the funds that are invested here now, with the exception of Eastern, Brio, Iroquois, and Empery would not be here if it wasn't for the merger. The merger was contingent on their investment. They weren't investing in Tapimmune, they were investing in Marker.
News 
Market Data 
Discover 
